Di Minno G, Ravasio R. Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy. Grhta [Internet]. 2021 Apr. 1 [cited 2024 Dec. 4];8(1):43-52. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2191